Informed Prostate Cancer Patient Support

Whack-a-Mole - by Brenna Humphreys - Q.O.L. Informed Prostate Cancer Support Group  ·  Newsletter Patient Advocacy & Research Translation | Recurrence & Advanced Disease Series Understanding Recurrence Whack-a-Mole: Why Prostate Cancer Comes Back — and the New Science of Hitting It Back A rising PSA after "successful" treatment is one of the most disorienting moments in the prostate cancer journey. Here is what recurrence actually means, why the moles keep popping up, and how the evidence for chasing them down has matured through 2026. By [Author] , IPCSG  ·  Reviewed for the membership  ·  Not medical advice — see disclaimer Bottom Line Up Front Between roughly one in five and two in five men treated for localized prostate cancer will eventually see their PSA climb again — a "biochemical recurrence" (BCR) that usually shows up years before anything is visible on a scan. This is the source of the whac...

From Trial to Treatment: Integrating Targeted Radionuclide Therapy Data Into Evidence-Based mCRPC Care - Integrating_Targeted_Radionuclide_Therapy_Data_Into_Evidence-Based_mCRPC_Care A patient-advocate briefing on the evidence, the fine print, and what's still unsettled — IPCSG Newsletter BLUF (Bottom Line Up Front):   Two PSMA-targeted radioligand therapies are now FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) — lutetium-177 vipivotide tetraxetan (Pluvicto), approved post-taxane in 2022 and expanded to pre-taxane use in March 2025 — alongside radium-223 (Xofigo), approved in 2013 for symptomatic bone-only disease. New Phase 3 data (PSMAddition) now show a benefit when Pluvicto is added even earlier, in hormone-sensitive disease, and Novartis has filed for that expanded use with decisions expected in the second half of 2026. Not every radioligand candidate is panning out, however: Lantheus disclosed in 2026 SEC filings that it will not file...

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial | Trials | JAMA Internal Medicine | JAMA Network IPCSG Newsletter — Clinical Update A review of the SPIRIT trial, the 2026 FDA/HHS label reconsideration, and where the guidelines now stand BLUF (Bottom Line Up Front):   For decades, a history of prostate cancer was treated as an almost automatic disqualifier for testosterone replacement therapy (TRT), regardless of how low-risk the cancer was or how long a man had been disease-free. That position was never based on a randomized trial — it was based on fear, extrapolated from the fact that androgen deprivation shrinks advanced prostate cancer. The first placebo-controlled randomized trial designed to actually test the question, the SPIRIT trial, has now reported results: 12 weeks of TRT in men with low-grade, organ-confined disease who were disease-free after radical prostatectomy produced zero cases of biochemical recu...

Study Warns on Sedentary Behavior and Cancer Mortality | MedPage Today IPCSG Newsletter · Research Digest Does Exercise Extend Life After a Prostate Cancer Diagnosis? What randomized trials, large cohort studies, and the newest 2025–2026 research actually show — and where the evidence still runs out. IPCSG Newsletter | July 2026 BLUF — Bottom Line Up Front Physical activity after a prostate cancer diagnosis is consistently associated with lower rates of death from prostate cancer and from all causes in large observational cohorts — with the biggest apparent benefit tied to vigorous activity (roughly 3+ hours a week) and to men who have had surgery rather than radiation. But no completed randomized controlled trial has yet proven that exercise causes longer survival specifically in prostate cancer, the way one now has in colon cancer (the CHALLENGE trial, NEJM , June 2025). The definitive prostate trial, INTERVAL‑GAP4, could not recruit enough men a...